🔖
Cite This Article
LEE, A. (2022). Fibrillarin antibodies in systemic sclerosis. Archives of Rheumatology, Cilt: 37 - Sayı: 2, 311–312. https://ajindex.com/articles/447984
Journals / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 2
Fibrillarin antibodies in systemic sclerosis
- Journal
- Archives of Rheumatology
- Pages
- 311–312
- Publication Date
- 2022-10-11
- DOI
- —
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗References (8)
- van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47
- Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001;40:1157-62
- Sousa SI, Fernandes S, Estanqueiro P, Zilhão C, Resende C, Ramos F, et al. Juvenile systemic sclerosis: Review of 15 patients. Pediatr Rheumatol 2014;12(Suppl 1):P118
- Tall F, Dechomet M, Riviere S, Cottin V, Ballot E, Tiev KP, et al. The clinical relevance of antifibrillarin (anti- U3-RNP) autoantibodies in ystemic sclerosis. Scand J Immunol 2017;85:73-9
- Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada-Y-Martin R, Pedroza C, et al. Antifibrillarin antibodies are associated with native North American ethnicity and poorer survival in systemic sclerosis. J Rheumatol 2017;44:799-805
- Benyamine A, Bertin D, Resseguier N, Heim X, Bermudez J, Launay D, et al. Quantification of antifibrillarin (anti-U3 RNP) antibodies: A new insight for patients with systemic sclerosis. Diagnostics (Basel) 2021;11:1064
- Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003;5:80-93
- Lee AY, Hudspeth AR, Adelstein S. The concordance of serial ANA tests in an Australian tertiary hospital pathology laboratory. Pathology 2016;48:597-601